Lake Street analyst Chad Messer initiated coverage of OS Therapies (OSTX) with a Buy rating and $19 price target Top line data from a Phase 2b trial of OST-HER2 in recurrent osteosarcoma supports filing for accelerated approval this year, says the analyst, who forecasts the drug could reach market around year-end and sees a $400M peak U.S. market opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX: